Bio-Matrix Scientific Group, Inc.’s (BMSN) RegenBioPharma Responds to FDA Comments for HemaXellerate in Preparation of Clinical Trials
Bio-Matrix Scientific subsidiary RegenBioPharma, Inc. today said it has submitted to the U.S. Food and Drug Administration its response to the agency’s comments regarding the company’s IND#15376, which covers the use of HemaXellerate for treatment of immune suppressant resistant aplastic anemia. In its response, RegenBioPharma provided new data demonstrating HemaXellerate’s ability to accelerate stem cell recovery after chemotherapeutic injury. While the possibility exists that the FDA may request additional comments, RegenBioPharma said it is confidant in its response as it looks forward to advancing HemaXellerate to clinical trials. "We are pleased with the responses that we have provided to…